| Source: |
| Type: |
| Glutaminyl Cyclase (QC / QPCT) — an enzyme that catalyzes conversion of N-terminal glutamate or glutamine residues into pyroglutamate. In Alzheimer’s disease, QC contributes to formation of pyroglutamate-modified amyloid-β (pE-Aβ), which is relatively aggregation-prone, protease-resistant, and neurotoxic. QC inhibition is therefore being investigated as a strategy to reduce pathogenic pE-Aβ formation. Typical modulation in Alzheimer’s disease: ↑ QC activity/expression is generally considered detrimental because it can increase formation of pyroglutamate Aβ; therapeutic modulation is ↓ QC/QPCT. Typical modulation in cancer: Context-dependent. QPCT has emerging roles in tumor biology and immune regulation in selected cancers, but there is not a sufficiently universal cancer-direction relationship to classify it broadly as consistently ↑ or ↓ across malignancies. |
| - | Study, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1642 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid